Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial

1. Platzbecker, U.
2. Santini, V.
3. Fenaux, P.
4. Sekeres, M.A.
5. Savona, M.R.
6. Madanat, Y.F.
7. Díez-Campelo, M.
8. Valcárcel, D.
9. Illmer, T.
10. Jonášová, A.
11. Bělohlávková, P.
12. Sherman, L.J.
13. Berry, T.
14. Dougherty, S.
15. Shah, S.
16. Xia, Q.
17. Sun, L.
18. Wan, Y.
19. Huang, F.
20. Ikin, A.
21. Navada, S.
22. Feller, F.
23. Komrokji, R.S.
24. Zeidan, A.M.